Academic Journal
Q1Cardiology and Therapy
About Cardiology and Therapy
Cardiology and Therapy is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 1.011 and H-index of 31.
Coverage: 2012-2026. Research categories: Cardiology and Cardiovascular Medicine (Q1).
Verified field sources
- Journal Impact Factor: 2.7 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2024 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Atrial Fibrillation Management and Outcomes; Antiplatelet Therapy and Cardiovascular Diseases; Cardiac Valve Diseases and Treatments; Heart Failure Treatment and Management; Acute Myocardial Infarction Research; Cardiac Imaging and Diagnostics.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Cardiovascular Outcomes Among Adults with Type 2 Diabetes or Obesity Receiving Carbohydrate-Reduced Nutrition via Telemedicine: A Retrospective Claims-Based Cohort Study
Caroline G. P. Roberts, Priya V. Shanmugam, Shaminie J. Athinarayanan, Adam J. Wolfberg et al.
2026-10-02 · DOI: 10.1007/s40119-026-00478-0Comparative Effectiveness of TTR Stabilizers for the Treatment of ATTR-CM Using Real-World Evidence
Richard Wright, Trejeeve Martyn, Allison Keshishian, Elizabeth Nagelhout et al.
2026-09-23 · DOI: 10.1007/s40119-026-00476-2Adverse Remodeling and Prognostic Significance of the Systemic Right Ventricle Across Congenital Heart Disease Subtypes
Kernfan Puthikitakawiwong, Chodchanok Vijarnsorn, Teerapong Tocharoenchok, Jarupim Soongswang et al.
2026-09-18 · DOI: 10.1007/s40119-026-00477-1Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
Carlo Fumagalli, Francesco Cappelli, Mathew S. Maurer, Fabian aus dem Siepen et al.
2026-09-11 · DOI: 10.1007/s40119-026-00474-4Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Marianna Fontana, Alberto Aimo, Martha Grogan, Maria Generosa Crespo-Leiro et al.
2026-09-04 · DOI: 10.1007/s40119-026-00475-3Polyneuropathy Assessment and Treatment Patterns in Patients with Hereditary Transthyretin Amyloidosis
Nicholas Streicher, Hermela Wubet
2026-09 · DOI: 10.1007/s40119-026-00472-6Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT
Mathew S. Maurer, Perry Elliott, Jeffery W. Kelly, Mazen Hanna et al.
2026-08-27 · DOI: 10.1007/s40119-026-00468-2Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis
Fabian aus dem Siepen, Angela Dispenzieri, Mazen Hanna, Martin Carlsson et al.
2026-08-27 · DOI: 10.1007/s40119-026-00464-6Functional Stability Measured by Changes in the 6-min Walk Test in Patients Treated with Tafamidis Versus Placebo: Post hoc Analysis from ATTR-ACT
Ronald Witteles, Mazen A. Hanna, Martha Grogan, Perry Elliott et al.
2026-08-27 · DOI: 10.1007/s40119-026-00471-7Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension
Thibaud Damy, Ronald Witteles, Francesco Cappelli, Ronnie Wang et al.
2026-08-27 · DOI: 10.1007/s40119-026-00470-8Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
Andrew Carlson, Zaid A. Zayyad, Stefanie Driesenga, Peter Boxley et al.
2026-09 · DOI: 10.1007/s40119-026-00473-5ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis
Roman Pfister, Lars Michel, Marcel Schulze, Kai Vogtländer et al.
2026-09 · DOI: 10.1007/s40119-026-00466-4Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern China
Hongye Ren, Magnus Fugger, Ying Wang, Zewei Shen et al.
2026-09 · DOI: 10.1007/s40119-026-00467-3Transthyretin Amyloid Cardiomyopathy in Women: Epidemiology, Diagnostic Delay, and Clinical Implications
Avni Madhani, Bhavya Ancha, Kevin M. Alexander, Joban Vaishnav et al.
2026-09 · DOI: 10.1007/s40119-026-00463-7Advanced Cardiac Imaging Techniques for Detection of Myocardial Ischemia in Children with Coronary Artery Abnormalities
Justin B. Jin, Jason L. Williams, Siew May Wang, Simon Lee et al.
2026-09 · DOI: 10.1007/s40119-026-00469-1Concomitant Versus Staged Percutaneous Cervicocerebral Artery Revascularization with Coronary Artery Bypass Grafting
Jinwei Zhang, Liaoming He, Chenzhen Xu, Chuanjie Yue et al.
2026-09 · DOI: 10.1007/s40119-026-00465-5Real-World Analysis of the Association Between Systemic Inflammation, Cardiovascular Events, and Economic Burden Among Patients with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease
Chi Nguyen, Radha Ryali, Jeffrey R. Skaar, Wing Chow et al.
2026-09 · DOI: 10.1007/s40119-026-00459-3Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice
Marianna Fontana, Francesco Cappelli, Julian D. Gillmore, Laura Obici et al.
2026-09 · DOI: 10.1007/s40119-026-00461-9Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update?
Diona Gjermeni, Kevin M. Alexander, James L. Januzzi, Kenneth W. Mahaffey et al.
2026-09 · DOI: 10.1007/s40119-026-00462-8The ‘Chloride Theory’ for Heart Failure Pathophysiology: An Updated Narrative Review 2025
Hajime Kataoka
2026-09 · DOI: 10.1007/s40119-026-00460-wReviews
Community Reviews
Version History
October 2, 2026 at 8:25 pm
October 2, 2026